Edgar Filing: Guiheen Lawrence P. - Form 4

Guiheen Law	vrence P.										
Form 4											
March 15, 20)19										
FORM	14								PPROVAL		
	UNITED	STATES		RITIES A shington			COMMISSION	N OMB Number:	3235-0287		
Check thi								Expires:	January 31,		
if no longer subject to Section 16. STATEMENT OF CHANGES IN BENI SECURITIE						ICIAL O	WNERSHIP OF	Estimated	Estimated average burden hours per		
Form 4 or								response	0.5		
obligation may cont	Form 5 obligations may continue.Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,See InstructionSection 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type F	Responses)										
1. Name and A Guiheen Lav	2. Issuer Name and Ticker or Trading Symbol ADMA BIOLOGICS, INC. [ADMA				5. Relationship of Reporting Person(s) to Issuer						
		3. Date of Earliest Transaction					Check all applicable)				
(Last) C/O ADMA STATE RO	BIOLOGICS, I		(Month/	Day/Year)	ransaction		X Director Officer (giv below)		% Owner her (specify		
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
RAMSEY, I	NJ 07446						Form filed by Person	More than One R	eporting		
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned		
	2. Transaction Date (Month/Day/Year)	2A. Deeme Execution I any (Month/Da	Date, if	3. Transactic Code (Instr. 8)	4. Securiti onAcquired Disposed (Instr. 3, 4	(A) or of (D)	Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Amount	(D) Price	(Instr. 3 and 4)				
Reminder: Rep	ort on a separate line	e for each cla	ass of sec	urities bene	-	-	-				
					inforn requir	nation cont ed to resp ys a curre	spond to the colle tained in this form ond unless the fo ntly valid OMB co	i are not rm	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: Guiheen Lawrence P. - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Year) (Instr. 8	(Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)					
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 3.89	03/13/2019	A		30,000		<u>(1)</u>	03/13/2029(2)	Common Stock	30,000

Reporting Owners

Reporting Owner Name / Address	Relationships								
	Director	10% Owner	Officer	Other					
Guiheen Lawrence P. C/O ADMA BIOLOGICS, INC. 465 STATE ROUTE 17 RAMSEY, NJ 07446	Х								
Signatures									
/s/ Lawrence P. Guiheen, by Brian Attorney-in-fact	03/15/2019								

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.
- (2) The option terminates on the earlier of (i) March 13, 2029 and (ii) the one-year anniversary of the reporting person's ceasing to serve as a director of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.